-
RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
Authors:
Paul Bertin,
Jarrid Rector-Brooks,
Deepak Sharma,
Thomas Gaudelet,
Andrew Anighoro,
Torsten Gross,
Francisco Martinez-Pena,
Eileen L. Tang,
Suraj M S,
Cristian Regep,
Jeremy Hayter,
Maksym Korablyov,
Nicholas Valiante,
Almer van der Sloot,
Mike Tyers,
Charles Roberts,
Michael M. Bronstein,
Luke L. Lairson,
Jake P. Taylor-King,
Yoshua Bengio
Abstract:
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not…
▽ More
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation. Our small scale wet lab experiments only account for evaluation of ~5% of the total search space. After only 3 rounds of ML-guided in vitro experimentation (including a calibration round), we find that the set of drug pairs queried is enriched for highly synergistic combinations; two additional rounds of ML-guided experiments were performed to ensure reproducibility of trends. Remarkably, we rediscover drug combinations later confirmed to be under study within clinical trials. Moreover, we find that drug embeddings generated using only structural information begin to reflect mechanisms of action. Prior in silico benchmarking suggests we can enrich search queries by a factor of ~5-10x for highly synergistic drug combinations by using sequential rounds of evaluation when compared to random selection, or by a factor of >3x when using a pretrained model selecting all drug combinations at a single time point.
△ Less
Submitted 2 March, 2023; v1 submitted 6 February, 2022;
originally announced February 2022.
-
Utilising Graph Machine Learning within Drug Discovery and Development
Authors:
Thomas Gaudelet,
Ben Day,
Arian R. Jamasb,
Jyothish Soman,
Cristian Regep,
Gertrude Liu,
Jeremy B. R. Hayter,
Richard Vickers,
Charles Roberts,
Jian Tang,
David Roblin,
Tom L. Blundell,
Michael M. Bronstein,
Jake P. Taylor-King
Abstract:
Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development…
▽ More
Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of small molecules and biologics, and drug repurposing. Whilst the field is still emerging, key milestones including repurposed drugs entering in vivo studies, suggest graph machine learning will become a modelling framework of choice within biomedical machine learning.
△ Less
Submitted 10 February, 2021; v1 submitted 9 December, 2020;
originally announced December 2020.
-
Sparse Dynamic Distribution Decomposition: Efficient Integration of Trajectory and Snapshot Time Series Data
Authors:
Jake P. Taylor-King,
Cristian Regep,
Jyothish Soman,
Flawnson Tong,
Catalina Cangea,
Charlie Roberts
Abstract:
Dynamic Distribution Decomposition (DDD) was introduced in Taylor-King et. al. (PLOS Comp Biol, 2020) as a variation on Dynamic Mode Decomposition. In brief, by using basis functions over a continuous state space, DDD allows for the fitting of continuous-time Markov chains over these basis functions and as a result continuously maps between distributions. The number of parameters in DDD scales by…
▽ More
Dynamic Distribution Decomposition (DDD) was introduced in Taylor-King et. al. (PLOS Comp Biol, 2020) as a variation on Dynamic Mode Decomposition. In brief, by using basis functions over a continuous state space, DDD allows for the fitting of continuous-time Markov chains over these basis functions and as a result continuously maps between distributions. The number of parameters in DDD scales by the square of the number of basis functions; we reformulate the problem and restrict the method to compact basis functions which leads to the inference of sparse matrices only -- hence reducing the number of parameters. Finally, we demonstrate how DDD is suitable to integrate both trajectory time series (paired between subsequent time points) and snapshot time series (unpaired time points). Methods capable of integrating both scenarios are particularly relevant for the analysis of biomedical data, whereby studies observe population at fixed time points (snapshots) and individual patient journeys with repeated follow ups (trajectories).
△ Less
Submitted 11 June, 2020; v1 submitted 9 June, 2020;
originally announced June 2020.
